Sustained-Release Injectable Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustained-Release Injectable Drug Delivery
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s6-s13

References

1. J. Prettyman, Medsurg Nurs. 14 (2), 93–98 (2005).

2. V.R. Sinha and A. Trehan, J. Control. Release 90 (3), 261–280 (2003).

3. A. Hatefi and B. Amsden, J. Control. Release 80 (1–3), 9–28 (2002).

4. C.B. Packhaeuser et al., Eur. J. Pharm. Biopharm. 58 (2), 445–455 (2004).

5. D. Chitkara et al., Macromol. Biosci. 6 (12), 977–990 (2006).

6. H.M. Mansour et al., Int. J. Mol. Sci. 11 (9), 3298–3322 (2010).

7. A. Jostel and S.M. Shalet, Treat. Endocrinol. 5 (3), 139–145 (2006).

8. Y. Capan et al., AAPS PharmSciTech 4 (2), E28 (2003).

9. Z.H. Gao et al., Peptides 30 (10), 1874–1881 (2009).

10. B.H. Woo et al., Pharm. Res. 18 (12), 1747–1553 (2001).

11. S. Giovagnoli et al. AAPS PharmSciTech 5 (4), Article 51 (2004).

12. B.A. Dani and P.P. DeLuca, AAPS PharmSciTech 2 (4), 22 (2001).

13. B.A. Dani et al., AAPS PharmSciTech 3 (3), E21-end page (2002).

14. P.C. Naha, V. Kanchan, and A.K. Panda, J. Biomater. Appl. 24 (4), 309–325 (2009).

15. D.B. Shenoy et al. Drug Dev. Ind. Pharm. 29 (5), 555–563 (2003).

16. G. Jiang, W. Qiu, and P.P. DeLuca, Pharm. Res. 20 (3), 452–459 (2003).

17. Y. Capan et al., J. Control. Release 60 (2–3), 279–286 (1999).

18. Y. Capan et al., Pharm. Res. 16 (4), 509–513 (1999).

19. S. Gebrekidan, B.H. Woo, and P.P. DeLuca, AAPS PharmSciTech 1 (4), E28 (2000).

20. R. D'Souza, S. Mutalik, and N. Udupa, Drug Dev. Ind. Pharm. 32 (2), 175–184 (2006).

21. J.Y. Lee et al., Int. J. Pharm. 392 (1–2), 51–56 (2010).

22. Y.S. Lee et al., Int. J. Pharm . 383 (1–2), 244–254 (2010).

23. D.B. Shenoy, R.J. D'Souza, and N. Udupa, J. Microencapsul. 19 (4), 523–535 (2002).

24. V.R. Sinha and A. Trehan, Drug. Deliv. 15 (6), 365–372 (2008).

25. T. Nahata and T.R. Saini, Drug Dev. Ind. Pharm. 34 (7), 668–675 (2008).

26. T. Nahata and T.R. Saini, J. Microencapsul. 25 (6), 426–433 (2008).

27. C. Cui, V.C. Stevens, and S.P. Schwendeman, Vaccine 25 (3), 500–509 (2007).

28. Y.D. Liu et al., Drug Dev. Ind. Pharm. 32 (1), 85–94 (2006).

29. S. Jhunjhunwala et al., J. Control. Release 133 (3), 191–197 (2009).

30. T.R. Kumar, K. Soppimath, and S.K. Nachaegari, Curr. Pharm. Biotechnol. 7 (4), 261–276 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here